Perspective Therapeutics, Inc.

Historical 13F Holders

Symbol
CATX
CUSIP
46489V302
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 46489V302 since 12/18/2024, newest first.

Filer % of Class Filed
Lantheus Holdings, Inc. 13D/A Amendment 3
7.7% 9/23/2026
Event 9/21/2026
Lantheus Holdings, Inc. 13D/A Amendment 2
10.0% 9/4/2026
Event 5/15/2024
Millennium Management LLC 13G/A Amendment 1
5.5% 8/13/2026
Event 8/7/2026
State Street Corp 13G 5.3% 8/7/2026
Event 6/30/2026
BlackRock, Inc. 13G 6.8% 7/29/2026
Event 6/30/2026
Millennium Management LLC 13G
5.3% 7/20/2026
Event 7/13/2026
Millennium Management LLC 13G
4.3% 6/30/2026
Event 6/23/2026
Morgan Stanley 13G/A Amendment 1 2.6% 5/12/2026
Event 3/31/2026
BlackRock, Inc. 13G/A Amendment 1 4.6% 4/27/2026
Event 3/31/2026
Avidity Partners Management LP 13G
5.3% 3/10/2026
Event 2/20/2026
Morgan Stanley 13G 6.0% 2/12/2026
Event 12/31/2025
Commodore Capital LP 13G
9.9% 2/9/2026
Event 2/2/2026
TCG Crossover GP II, LLC 13G
6.9% 2/6/2026
Event 2/3/2026
Qatar Investment Authority 13G 6.2% 2/5/2026
Event 2/4/2026
FMR LLC 13G/A Amendment 3
0.4% 12/5/2025
Event 11/28/2025
FMR LLC 13G/A Amendment 2
8.2% 11/7/2025
Event 10/31/2025
Janus Henderson Group PLC 13G/A Amendment 1 0% 2/14/2025
Event 12/31/2024
Avidity Partners Management LP 13G/A Amendment 1
4.2% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 3 106 k $291 k
2026 Q2 133 89.3 M $306 M
2026 Q1 144 84.6 M $351 M
2025 Q4 119 36.4 M $102 M
2025 Q3 106 43.0 M $147 M
2025 Q2 100 42.2 M $145 M
2025 Q1 114 44.1 M $94.0 M
2024 Q4 141 47.1 M $150 M
2024 Q3 132 49.1 M $654 M
2024 Q2 106 38.7 M $386 M